Abstract

The development of site-specific recombinases (SSRs) as genome editing agents is limited by the difficulty of altering their native DNA specificities. Here we describe Rec-seq, a method for revealing the DNA specificity determinants and potential off-target substrates of SSRs in a comprehensive and unbiased manner. We applied Rec-seq to characterize the DNA specificity determinants of several natural and evolved SSRs including Cre, evolved variants of Cre, and other SSR family members. Rec-seq profiling of these enzymes and mutants thereof revealed previously uncharacterized SSR interactions, including specificity determinants not evident from SSR:DNA structures. Finally, we used Rec-seq specificity profiles to predict off-target substrates of Tre and Brec1 recombinases, including endogenous human genomic sequences, and confirmed their ability to recombine these off-target sequences in human cells. These findings establish Rec-seq as a high-resolution method for rapidly characterizing the DNA specificity of recombinases with single-nucleotide resolution, and for informing their further development.

The development of site-specific recombinases as genome editing tools is limited by the difficulty of altering their DNA sequence specificity. Here the authors present Rec-seq, a method for identifying specificity determinants and off-target substrates of recombinases in an unbiased manner.

Details

Title
High-resolution specificity profiling and off-target prediction for site-specific DNA recombinases
Author
Bessen, Jeffrey L 1   VIAFID ORCID Logo  ; Afeyan, Lena K 1 ; Dančík Vlado 2 ; Koblan, Luke W 1 ; Thompson, David B 3 ; Leichner Chas 4 ; Clemons, Paul A 2   VIAFID ORCID Logo  ; Liu, David R 1   VIAFID ORCID Logo 

 Broad Institute of Harvard and MIT, Merkin Institute of Transformative Technologies in Healthcare, Cambridge, USA (GRID:grid.66859.34); Harvard University, Department of Chemistry and Chemical Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard University, Howard Hughes Medical Institute, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Broad Institute of Harvard and MIT, Chemical Biology and Therapeutics Science Program, Cambridge, USA (GRID:grid.66859.34) 
 Harvard University, Department of Chemistry and Chemical Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard University, Howard Hughes Medical Institute, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Google Inc., Mountain View, USA (GRID:grid.420451.6) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2215530428
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.